By Colin Kellaher


Pfizer Inc. and BioNTech SE on Thursday said a Phase 3 study showed a booster dose of their Covid-19 vaccine in individuals 16 years of age and older saw a relative vaccine efficacy of 95.6% compared to those who didn't receive a booster.

The partners said a booster dose administered to those who had already received the primary two-dose series of their vaccine restored protection against Covid-19 to the high levels achieved after the second dose.

Pfizer and BioNTech said they plan to submit the data to regulatory agencies around the world to support licensure in the U.S. and other countries.

The U.S. Food and Drug Administration in September granted emergency approval of a third dose of the Pfizer/BioNTech vaccine for people 65 and older and certain other adults at high risk of severe illness. The agency Wednesday cleared the use of a booster dose in eligible individuals who completed a primary round with a different vaccine.


Write to Colin Kellaher at


(END) Dow Jones Newswires

October 21, 2021 07:34 ET (11:34 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more BioNTech Charts.
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more BioNTech Charts.